Pharma Research analyzed that exports fell short of expectations last month, and found that although the stock price plummeted 15%, both domestic demand and exports will grow in the fourth quarter, and there are many positive factors in performance.
Park Jong-hyeon, a researcher at Daol Investment Securities, stated in a report on the 2nd that “domestic medical device sales are expected to increase 58% to 66 billion won due to the peak season in the fourth quarter,” and “we maintain the forecast that exports will also exceed the second quarter, which was the highest ever.” The target share was 800,000 won, and the investment opinion remained the same.
Researcher Park pointed out that “concerns about derating (decrease in price/earnings ratio) about Pharma Research are interpreted as intensifying domestic competition due to the launch of new products,” but “sales growth continued even with the launch of competitive products within Skin Booster.” In terms of exports, shipments to the UK are scheduled for December, and considering that exports are busy in the fourth quarter due to the seasonal peak season, an increase in sales can be expected, he added. He emphasized, “Although the stock price plummeted due to the news that exports from the Customs Service fell short of market expectations in November, I expect that concerns will be resolved sequentially through medical tourism consumption data coming out on the 11th and customs service export data coming out next month.”
? Exports were low in November... Pharma Research and both domestic demand and exports were positive in the fourth quarter [Why Bio]
